CBD (cannabidiol) products work by interacting with the body's endocannabinoid system (ECS), a complex cell-signalling system that regulates various physiological and cognitive processes, including pain, mood, appetite, sleep, and immune function.

CBD is a non-psychoactive compound found in cannabis plants, and it interacts with the ECS by binding to receptors in the brain and throughout the body. The two main receptors that CBD interacts with are CB1 and CB2 receptors.

CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are found in peripheral organs, immune cells, and tissues. CBD does not bind directly to these receptors, but it can enhance their activity and modulate their signalling pathways.

CBD products can have a variety of effects on the body, depending on their concentration and formulation. Some of the potential benefits of CBD products include reducing inflammation, alleviating pain, improving sleep, reducing anxiety and depression, and improving overall mood and well-being.

However, it's important to note that more research is needed to fully understand the mechanisms by which CBD works and the extent of its therapeutic benefits. Additionally, CBD products may interact with other medications and may not be suitable for everyone. It's always important to consult with a healthcare provider before starting any new supplement or medication.

references 

1. Devinsky O, Marsh E, Friedman D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. PMID: 26724101.

2. Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 2. PMID: 26845349.

3. Pamplona FA, da Silva LR, Coan AC. Potential Clinical Benefits of CBD-Rich Cannabis Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-analysis. Front Neurol. 2018 Sep 12;9:759. doi: 10.3389/fneur.2018.00759. PMID: 30258398; PMCID: PMC6143706.

4. Iffland K, Grotenhermen F. An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies. Cannabis Cannabinoid Res. 2017;2(1):139-154. doi: 10.1089/can.2016.0034. PMID: 28861514; PMCID: PMC5569602.

5. Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial. Am J Psychiatry. 2019 Oct 1;176(10):911-922. doi: 10.1176/appi.ajp.2019.18101191. PMID: 31352884; PMCID: PMC6770351.

6. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs. 2018 Nov;78(17):1791-1804. doi: 10.1007/s40265-018-0992-5. PMID: 30242878.

7. Russo EB. Cannabidiol Claims and Misconceptions. Trends Pharmacol Sci. 2017 Aug;38(8):198-201. doi: 10.1016/j.tips.2017.06.006. Epub 2017 Jul 11. PMID: 28714575.

8. Shannon S, Opila-Lehman J. Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. Perm J. 2016 Fall;20(4):16-005. doi: 10.7812/TPP/16-005. PMID: 27768570; PMCID: PMC5101100.